Forbion Growth Opportunities Fund I (Forbion Growth I)

https://www.forbion.com

Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Boston. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Recent portfolio company successes include Inversago, Vectiv Bio, Versanis, Gyroscope, NewAmsterdam Pharma (NASDAQ: NAMS), Engene (NASDAQ: ENGN), and Replimune (NASDAQ: REPL). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *

	Start	2020-07-09 closing, first
	Group	Forbion (Group)
	Successor	Forbion Growth Opportunities Fund II (Forbion Growth II)
	Industry	Forbion Growth Opportunities Fund I (Forbion Growth I)
	Industry 2	LIFE SCIENCES
	Person	Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital)
	Person 2	Kersten, Dirk (Forbion 201810– General Partner before Inkef Capital + Gilde Healthcare)

	Region	Naarden
	Country	Netherlands
	City	n. a. Naarden
		Address record changed: 2021-04-24

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	360,000,000 (fund size at final closing (2021) 2021-04-20)

		* Document for »About Section«: Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion".

		Record changed: 2024-02-12